SCHEDULE: FMR LLC Reports 5.7% Stake in Lenz Therapeutics
Beneficial Ownership Filing (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting a combined beneficial ownership of 5.7% in Lenz Therapeutics Inc. as of August 31, 2026.
Summary
- FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, indicating their beneficial ownership of Lenz Therapeutics Inc. common stock.
- As of August 31, 2026, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 1,783,202.25 shares.
- This represents 5.7% of the class of securities.
- FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an insider (IN).
- The filing confirms that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a performance or strategic announcement.
Positives
- FMR LLC and Abigail P. Johnson maintain a significant beneficial ownership stake, indicating continued confidence or investment interest in Lenz Therapeutics Inc.
Risks
- The filing does not contain specific forward-looking statements or risk factors related to Lenz Therapeutics Inc.'s business operations, focusing solely on ownership details.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding Lenz Therapeutics Inc.'s future performance or strategy.
Management Comments
- FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual holders to report their ownership stakes. This filing indicates FMR LLC's ongoing investment in Lenz Therapeutics, a biotechnology company, which aligns with broader trends of institutional investment in the healthcare and life sciences sectors.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding significant ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date for Power of Attorney for FMR LLC. |
| 2023-01-26 | Effective date for Power of Attorney for Abigail P. Johnson. |
| 2023-01-10 | FMR LLC Schedule 13G filing date (referenced for Power of Attorney). |
| 2023-01-31 | FMR LLC Schedule 13G filing date (referenced for Power of Attorney). |
| 2026-08-31 | Date of Event Which Requires Filing of this Statement (Reporting period end date). |
| 2026-09-04 | Date of joint filing agreement. |
Keywords
Lenz Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.